Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women With Non-Metastatic Breast Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/4/2018 |
| Start Date: | August 19, 2015 |
| End Date: | August 2019 |
| Contact: | Mario Lacouture, MD |
| Phone: | 646-888-6014 |
A Prospective, Longitudinal Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women With Non-Metastatic Breast Cancer
The purpose of this study is to see how many patients develop hair, skin and nail changes due
to cancer treatments. The investigators would like to study the clinical factors, genetic
markers, and impact on patients' health-related quality of life to learn more about who is at
greater risk. We trust that the study will improve our understanding of how cancer patients
feel about their skin, hair, and nail conditions. This information will help us determine the
burden on breast cancer patients and survivors. It will also help us learn how to prevent
these conditions and it may improve the way we treat them and counsel patients.
to cancer treatments. The investigators would like to study the clinical factors, genetic
markers, and impact on patients' health-related quality of life to learn more about who is at
greater risk. We trust that the study will improve our understanding of how cancer patients
feel about their skin, hair, and nail conditions. This information will help us determine the
burden on breast cancer patients and survivors. It will also help us learn how to prevent
these conditions and it may improve the way we treat them and counsel patients.
Inclusion Criteria:
- Women newly diagnosed with non-metastatic breast cancer (stage 0-III, any receptor
type) at the time of starting chemotherapy (dd-AC-T, CMF, Newer Combination Regimens)
or endocrine therapy (tamoxifen, anastrozole, letrozole, exemestane)
- Women ≥ 18 years at the time of enrollment into the study
- Able to communicate in English and participate in the informed consent process
- Able to comply with the follow-up visits, assessments, answering questionnaires
Exclusion Criteria:
- Metastatic breast cancer
- Follow-up care/visits not scheduled at MSKCC
- Any current alopecia especially due to an active scalp and/or hair disorder (e.g.
alopecia areata), or a pre-existing condition with sequelae (e.g. scarring alopecia)
- Currently active or uncontrolled medical condition [e.g. thyroid disorder, auto-immune
connective tissue disease (e.g. SLE), BMT complications (GVHD)] or medication intake
(e.g. HRT), affecting scalp hair
- Prior systemic treatment for any malignancy
- Active secondary cancer requiring cytotoxic chemotherapy
- Planned (or a history of) radiation therapy to the head
- Vulnerable populations [e.g. decisionally impaired (cognitive, psychiatric),
terminally ill, prisoners], or patients who, in the opinion of the investigator have a
condition that precludes their ability to provide an informed consent
- Men
Volunteer Inclusion Criteria:
- Post menopausal women, with menopausal status defined as (per self report):
- Bilateral salpingo-oophorectomy independent of age
- If natural menopause, age ≥ 50 with cessation of menses for at least 12 months
- Or premenopausal women with premenopausal status defined as <53 years of age with no
cessation of menses
- Able to communicate in English and participate in the informed consent process
- Able to comply with the baseline assessments and answering questionnaires
- Women >/= 18 years at the time of enrollment into the study
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Mario Lacouture, MD
Phone: 646-888-6014
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
